Changes in Hong Kong stocks | mRNA concept stocks had the highest increase, Cansino Biotech (06185) rose more than 17%. Modena's new mRNA antigen therapy will be unveiled at the ESMO conference

Zhitongcaijing · 3d ago

The Zhitong Finance App learned that mRNA concept stocks had the highest gains. As of press release, Cansino Biotech (06185) rose 16.78% to HK$36.32; Genting Xinyao (01952) rose 4.29% to HK$29.18; Siludi Pharmaceuticals (01244) rose 1.94% to HK$2.89; and Jietai Technology-P (07666) rose 1.44% to HK$16.22.

According to the news, on September 21, Modena announced that three research abstracts on new individualized mRNA antigen therapies jointly developed with MSD were accepted and will be presented at the 2026 European Society of Medical Oncology (ESMO) conference to be held in October. Huaxin Securities believes that cancer vaccines are the main breakthrough direction for mRNA technology in the future. Infectious disease vaccines are constrained by epidemic prevention and control, and there is a large unmet demand in the field of cancer prevention and treatment. The number of cancer patients around the world continues to increase. mRNA cancer vaccines are the core path for the market value of mRNA technology to soar.

Notably, on August 25, Cansino Biotech and Deputh Biotech signed the “Strategic Cooperation Framework Agreement for Joint Development of Personalized mRNA Oncology Vaccines”. Previously, in the field of mRNA, Cansino Biotech has deployed mRNA vaccines for the development of indications such as glioblastoma, rhabdomyosarcoma, and cervical cancer. Genting Xinyao plans to conduct IIT Ib research on the mRNA vaccine EVM16 in the fourth quarter of 2026.